Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

Hospital executives weigh benefits, risks of health reform

Hospital executives are balancing their hopes that expanded coverage will provide a windfall for facilities now burdened by uncompensated care with their fears that government intervention, such as the possible creation of a public insurance option, could cut into their revenues, the Atlanta Journal-Constitution reports.

10 Sep 2009

Protox Therapeutics to present TRIUMPH clinical study update

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that Dr. Fahar Merchant, President & CEO of Protox Therapeutics, will present at the 11th Annual Rodman & Renshaw Healthcare Conference.

9 Sep 2009

Senators return to full plate, featuring health bills

"The focus on health care as Congress reconvenes Tuesday after its monthlong recess is nearly all-consuming," The Associated Press reports. "At stake, beyond the future of health care, is an accomplishment Democrats need to convince voters they deserve to remain in power." Financial legislation, consumer protections and clean energy are also still on the table in the Senate (Abrams, 9/8).

9 Sep 2009

Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males with moderate to severe benign prostatic hyperplasia (BPH), a common and bothersome urological condition that affects more than 50 million men worldwide.

8 Sep 2009

Scientists solve the mystery of zonulin's identity

It was nine years ago that University of Maryland School of Medicine researchers discovered that a mysterious human protein called zonulin played a critical role in celiac disease and other autoimmune disorders, such as multiple sclerosis and diabetes.

8 Sep 2009

Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier

Earlier this year, researchers at the University of Washington reported that they had developed a toxin-nanoparticle combination that inhibits brain cancer invasion when added to tumor cells growing in culture.

7 Sep 2009

New role discovered for sphingosine-1-phosphate

Virginia Commonwealth University School of Medicine researchers have discovered a new role for the bioactive lipid messenger, sphingosine-1-phosphate, or S1P, that is abundant in our blood - a finding that could lead to a new generation of drugs to fight cancer and inflammatory disease.

5 Sep 2009

Brain screening tests may do more harm than good

Researchers warn that paid-for brain scans - increasingly popular with healthy people who want to allay fears about undiagnosed brain cancer and stroke - may do more harm than good.

4 Sep 2009

First-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable prior year quarter. This increase was primarily generated from increased government contract revenue and from increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

3 Sep 2009

Interim Phase II data of Cotara reveals signs of efficacy in GBM patients

Peregrine Pharmaceuticals, Inc. today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer.

3 Sep 2009

GDC-0449 inhibits the Hedgehog signaling pathway

The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.

3 Sep 2009

Avastin increases survival rates in recurrent glioblastoma affected patients

The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.

3 Sep 2009

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

2 Sep 2009

JAMA study reveals the genetic signature of brain cancer

A pair of studies in the July 15 issue of the Journal of the American Medical Association (JAMA) spell out how much closer science has come to unraveling the genetic signature of brain cancer, according to a researcher at the University of Alabama at Birmingham (UAB). Boris Pasche, M.D., Ph.D., director of the UAB Division of Hematology and Oncology, believes these studies represent a new vanguard in the still-changing field of DNA analysis.

2 Sep 2009

New computer software capable of sifting through hundreds of cancer causing genetic mutations

Johns Hopkins engineers have devised innovative computer software that can sift through hundreds of genetic mutations and highlight the DNA changes that are most likely to promote cancer.

1 Sep 2009

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the dosing of the first patient in a Phase I clinical study of AR-12 (formerly OSU-03012) in adult patients with advanced or recurrent solid tumors or lymphoma.

28 Aug 2009

Lung Cancer Alliance condoles the death of Edward Kennedy

Laurie Fenton-Ambrose, President and CEO of Lung Cancer Alliance extended condolences to the family of Senator Edward Kennedy who died of brain cancer late last night.

27 Aug 2009

Sen. Edward M. Kennedy -- health care champion -- dies

Sen. Edward M. Kennedy had a hand in nearly every piece of health care legislation that moved through Congress during his eight-term Senate tenure. He died Tuesday night of brain cancer at age 77.

27 Aug 2009

More than 22,000 Americans expected to be diagnosed with a malignant brain tumor in 2009

It is expected that more than 22,000 Americans will be diagnosed with a malignant brain tumor in 2009. Senator Ted Kennedy's death from a brain cancer draws attention to a rare, but often fatal type disease. While the risk of developing brain cancer is relatively low, it is important to heed the warning signs and receive an accurate diagnosis.

27 Aug 2009

Will Kennedy's death add momentum to the health care push?

News reports examine the speculation, which has already begun, regarding the impact of Sen. Edward Kennedy's passing might have on the current health reform debate.

27 Aug 2009